文献速递哮喘

接受美泊利珠单抗治疗的重度难治性嗜酸性哮喘急性加重的炎症特征:MEX研究

The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
PubMed 文献 · Lancet Respir Med · 2021-05-07

MEX研究是一项多中心前瞻性观察队列研究,纳入145例接受美泊利珠单抗治疗的重度嗜酸性哮喘患者,共发生172次急性加重,其中96次在 rescue 治疗前完成评估。加重时痰嗜酸性粒细胞≥2%者FeNO更高、FEV1%pred更低、血嗜酸性粒细胞更高;而痰嗜酸性粒细胞<2%者CRP更高、痰中性粒细胞更高、更可能使用抗生素。FeNO是区分加重炎症表型的最有用指标。

要点

  • 美泊利珠单抗治疗期间急性加重可分为嗜酸性和非嗜酸性两种表型。
  • FeNO高提示嗜酸性加重,FeNO低伴CRP高提示感染驱动的非嗜酸性加重。
  • 非嗜酸性加重更可能接受抗生素治疗,嗜酸性加重肺功能下降更明显。

核心结论

  • 美泊利珠单抗治疗期间的急性加重是两种不同实体,可用FeNO largely 区分。
  • 非嗜酸性事件由感染驱动,表现为低FeNO和高CRP;嗜酸性加重则FeNO高。
  • 结果挑战对所有美泊利珠单抗治疗期间急性加重常规使用口服糖皮质激素的做法。

研究设计与样本

  • 多中心、前瞻性、观察性队列研究,在英国四个专科重度哮喘中心开展。
  • 参与者为18-80岁重度嗜酸性哮喘(GINA 4-5级)且符合美泊利珠单抗治疗条件者。
  • 所有参与者接受美泊利珠单抗100 mg皮下注射每4周一次。
  • 共发生172次急性加重,其中96次(56%)在开始 rescue 治疗前完成评估。

主要发现

  • 与未加重者相比,加重者在开始美泊利珠单抗前一年有更高的加重率和更多急诊就诊。

关键数值与推荐

  • 嗜酸性加重定义:痰嗜酸性粒细胞≥2%(SEHIGH);非嗜酸性定义:痰嗜酸性粒细胞<2%(SELOW)。
  • FeNO(≤20或≥50 ppb)是加重时炎症表型最有用的区分指标。

临床怎么用

  • 对美泊利珠单抗治疗期间急性加重应进行炎症表型分析,而非一律使用口服糖皮质激素。
  • 可用FeNO和CRP区分嗜酸性与非嗜酸性加重,指导治疗选择。
  • 非嗜酸性加重更可能需抗生素治疗,嗜酸性加重可能需调整生物制剂。

局限性

  • 探索性研究,主要终点为100次临床评估,实际完成96次评估。
  • 部分急性加重因患者无法到中心或已开始 rescue 治疗而未能评估。
  • 研究仅纳入符合美泊利珠单抗治疗条件的重度嗜酸性哮喘患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical trials with mepolizumab, a humanised monoclonal antibody against interleukin-5, show a 50% reduction in severe asthma exacerbations in people with severe eosinophilic asthma. Exacerbations in patients treated with mepolizumab seem to be different to exacerbations in those given placebo, as patients treated with mepolizumab report fewer symptoms, have a lower sputum eosinophil count, and smaller fall in peak expiratory flow. We aimed to investigate the inflammatory phenotype and physiological characteristics of exacerbation events in patients with severe eosinophilic asthma who were treated with mepolizumab. METHODS: This multicentre, prospective, observational cohort study was carried out at four UK specialist severe asthma centres. Participants were aged 18-80 years, with severe eosinophilic asthma (Global Initiative for Asthma steps 4 and 5), and were eligible for mepolizumab therapy. All participants received mepolizumab 100 mg subcutaneously every 4 weeks, had a scheduled study visit when stable on mepolizumab (≥3 months on treatment), and measured daily peak flow and completed symptoms diaries throughout the course of the study. Participants attended their study centre for unscheduled exacerbation assessment when symptoms worsened outside of their normal daily variation and before commencing rescue treatment. If a participant was unable to attend their study centre for exacerbation or had initiated rescue treatment before the study visit, clinical details of the missed exacerbation were collected by clinical staff. In this exploratory study, the endpoint was 100 clinical assessments at exacerbation completed across all sites for participants on mepolizumab before initiation of rescue treatment. Characteristics of those who had exacerbations on mepolizumab were compared with those who did not, peak flow and symptoms diaries were compared for assessed versus missed exacerbations, and exacerbation phenotypes defined by sputum eosinophil cell count were compared. The utility of fractional exhaled nitric oxide (FeNO) and C-reactive protein in determining exacerbation phenotype on mepolizumab treatment were also assessed. This study is registered with ClinicalTrials.gov, NCT03324230. FINDINGS: Between Nov 30, 2017, and May 29, 2019, 145 participants were enrolled and treated with mepolizumab, five were excluded from the analysis. 172 exacerbations occurred, with 96 (56%) assessed before commencing rescue treatment. Compared with patients who did not exacerbate, patients who exacerbated had a higher exacerbation rate and more emergency department attendances in the year before commencing mepolizumab. The change in peak expiratory flow at nadir in the assessed exacerbation group was mean -40·5 L/min (SD 76·3) versus mean -37·0 L/min (93·0; p=0·84) in the missed exacerbation group, and there was no difference in reported symptom burden. When comparing exacerbations with a high sputum eosinophil count (≥2%; SEHIGH) with exacerbations with a low sputum eosinophil count (<2%; SELOW), the SEHIGH exacerbations were FeNO high (median difference 33 parts per billion [ppb; 95% CI 8 to 87]; p=0·0004), with lower FEV1 percent predicted (mean difference -15·9% [-27·0 to -4·8]; p=0·0075), lower FEV1 to forced vital capacity ratio (mean difference -10·3 [-17·0 to -3·6]; p=0·0043), and higher blood eosinophil counts (median difference 40 cells per μL [20 to 70]; p=0·0009). By contrast, SELOW exacerbations had higher C-reactive protein concentrations (median difference 12·7 mg/L [3·5 to 18·5]; p<0·0001), higher sputum neutrophil counts (median difference 52·7% [34·5 to 59·2]; p<0·0001), and were more likely to be treated with antibiotics (p=0·031). FeNO (≤20 or ≥50 ppb) was the most useful discriminator of inflammatory phenotype at exacerbation. The most common adverse event was hospital admission due to asthma exacerbation (17 [50%] of 34 events), none of the adverse events were study procedure related. INTERPRETATION: Exacerbations on mepolizumab are two distinct entities, which can largely be differentiated using FeNO: non-eosinophilic events are driven by infection with a low FeNO and high C-reactive protein concentration, whereas eosinophilic exacerbations are FeNO high. The results of the MEX study challenge the routine use of oral corticosteroids for the treatment of all asthma exacerbation events on mepolizumab, as well as the switching of biological therapies for treatment failure without profiling the inflammatory phenotype of ongoing asthma exacerbations. The results highlight clinically available tools to enable profiling of these residual exacerbations in patients treated with mepolizumab. FUNDING: UK Medical Research council.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. McDowell PJ, Diver S, Yang F, et al. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. Lancet Respir Med. 2021. PMID: 33971168. doi:10.1016/S2213-2600(21)00004-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。